David Tanen

Kirax Corp. researches, develops, manufactures and distributes pharmaceutical products. The firm provides specialty care therapies to treat oncology, pain, inflammation, acute, and supportive care areas of unmet medical need. The company was founded by Mark E. Pruzanski, David M. Tanen and Edmundo Muniz in 2005 and is headquartered in Bonita Springs, FL.

Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA.

Part of Two River Group Holdings LLC, Riverbank Capital Securities, Inc. deals securities. The private company is based in New York, NY.

Danube Pharmaceuticals, Inc. provides bio pharmaceutical services. It engages in the discovery and development of therapies and devices for ophthalmology. The firm's products include DNB-001, a small molecule for the treatment of glaucoma. The company was founded in 2006 and is headquartered in New York, NY.

Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA.

Two River Consulting LLC provides management consulting services. The private company is based in Franklin Lakes, NJ. The company was founded by David M. Tanen.

VV Manager LLC (Vida Ventures) is a venture capital firm founded in 2017 by Arie Belldegrun, Arjun Goyal and Stefan Vitorovic. The firm is headquartered in Boston, Massachusetts.

Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY.

76Bio, Inc. is a private company that aims to develop transformational therapies for patients with life-threatening diseases. The company is based in New York, NY. The company focuses on pioneering the next generation of degradation by design. 76Bio was founded by Joshua A. Kazam, David M. Tanen, Marius Pop, Christopher Wilfong, Ben Stone, Angela Koehler, Arie S. Belldegrun, and K. Dane Wittrup. Christopher Wilfong has been the CEO since incorporation.